No. Schramkm is right on. Author Corey is a big wheel at hvtn. He concludes the article by saying 'if it works...', reiterating the 'hack science' he is promoting as he has no clue. I think hvtn put on the brakes for govx when they were establishing their relationship with P5/Gates Foundation deep pockets/influence at failed RV144 - which used aidsvax. If new study happens should have some numbers to post against RV144...if hvtn 114 ever gets off the ground......
Kootch, Peru has been mentioned. On the Global solutions for Infectious Diseases, HVTN 114 has the Study location listed as USA/Peru.AIDSVAX® Program: Current Trials
From the website:
"GSID serves the manufacturing and product sponsor for the AIDSVAX® B/E vaccine, which continues to be used in a number of HIV vaccine trials around the world. The following table represents the current and planned trials"
....not sure waiting. Looking at the AMP study my only connection is that one of the clinics is Emory U's Hope clinic and in reference to other AMP study countries there is Peru. I thought that was mentioned once before in another Geovax pr. but not sure.
The next human clinical trial of GOVX-B11 is expected to begin in mid-2016. The trial, designated HVTN 114, will investigate the effect of a late protein boost for vaccinated individuals who participated in the HVTN 205 Phase 2a trial. Protein boosts may augment protective antibody responses that can block virus infections and/or kill infected cells through antibody dependent cellular cytotoxicity (ADCC). The one partially successful HIV vaccine trial in Thailand (the RV144 trial) included a protein boost and the HVTN has requested that such a boost be tested for the GeoVax DNA/MVA vaccine regimen
No I don't think so. Fucci of NIH has been funding Broadly Neutralizing antibodies for years now.
Dr Robinson said years ago they would not work , She has been trumpeting NON Neutralizing antibodies, maybe that's why we get no love from NIH anymore. Cant wait untill Fucci is gone.
schramekm, rss, kootch
Do the references in this Forbes article have any connection to GOVX?
Duke university Phase 1 study injecting modified Polio gene into brain tumors. The claim virus strips Cancer cells of their protective coating which makes C cells INVISABLE to immune system, therefore allowing Im system to kill cancer cells.
1 woman cured, another doctor claims cure for himself, others with extended QUALITY of life spans...
Maybe we DO have a Dog in this hunt.
Also worth reading the Hemorrhagic Fever Update:
Except - In addition to protecting people in Africa, it is intended to prevent the spread of disease to the US, as with the last outbreak, and for preparedness against terrorist release of any of these four bio-threat pathogens (EBOV, SUDV, MARV, and LASV). The initial markets for the TV vaccine are both NGOs such as Gavi, the vaccine alliance and the Bill & Melinda Gates Foundation, as well as US and foreign governments.
Worth checking out the Technology Pipeline link.
Downsized to 5 candidates, but more information is offered.
Our primary collaboration on the development of a ZIKV vaccine is with the University of Georgia (UGA), which will develop animal models and perform mouse studies. The US Centers for Disease Control (CDC) is developing its own animal models (AG129 mice, developed for dengue vaccine testing) and will serve as a backup strategy. Collaborating researchers at the Rocky Mountain Laboratories are developing non-human primate models for ZIKV testing. ZIKV and reagents will be supplied by the University of Texas Medical Branch (UTMB). Working with multiple collaborators and multiple candidate vaccines, we will manage risk by providing multiple paths toward the selection of the best vaccine candidate.
Our Immuno-Oncology Development Efforts. GeoVax has established a collaboration with Dr. Olivera Finn, a leading expert in cancer immunotherapy at the University of Pittsburg. Dr. Finn was the first to show that many tumors express an abnormal form of cell surface-associated Mucin 1 (MUC1) protein that is recognized by the immune system as foreign. Recently the NCI ranked MUC1 second in importance of 75 tumor-associated antigens.Given this, we are developing our MVA-VLP vaccine platform to deliver abnormal forms of MUC1 with the goal of raising protective anti-tumor antibodies and T cell responses in cancer patients.